Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 5, 2002, Pages 451-453

  Saad, Everardo D ^a   Kraut, Eric H ^a   Hoff, Paulo M ^a   Moore Jr , Dennis F ^a   Jones, Donnah ^a   Pazdur, Richard ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Dolastatin 10; Phase II trial

Indexed keywords

ALKALINE PHOSPHATASE; CREATININE; DOLASTATIN 10; NCS 376128;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT INDICATION; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES;

EID: 0036795186     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200210000-00005     Document Type: Article

References (12)

1. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin-10. J Am Chem Soc 1987;109:6883-5.
2. Bai R, Pettit GR, Hamel E. Dolastatin-10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990;39:1941-9.
3. Kalemkerian GP, Ou X, Adil MR, et al. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 1999;43:507-15.
4. Waud WR, Dykes DJ, Pettit GR, et al. Preclinical antitumor activity of dolastatin-10 [Abstract 2282]. Proc Am Assoc Cancer Res 1993;34:383.
5. Aherne GW, Hardcastle A, Valenti M, et al. Antitumor evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother Pharmacol 1996;38:225-32.
6. Pitot HC, McElroy EA, Reid JM, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999;5:525-31.
7. Madden T, Tran HT, Beck D, et al. Novel marine-derived anticancer agents: a phase I clinical pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 2000;6:1293-301.
8. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
9. Krug LM, Miller VA, Kalemkerian GP, et al. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol 2000;11:227-8.
10. Margolin KA, Longmage J, Gandara DR, et al. Dolastatin-10 (DOLA) in metastatic melanoma (MEL): a phase II trial of the California Cancer Consortium [Abstract 2243]. Proc Am Soc Clin Oncol 2000;19:569a.
11. Madden T, Tran HT, Felix E, et al. Dolastatin 10 (dola 10) administered with G-CSF allows substantial escalation of the maximum tolerated dose (MTD) in patients (pts) with advanced solid tumors [Abstract 300]. Clin Cancer Res 1999;5(suppl):3789S.
12. Toppmeyer DL, Slapak CA, Croop J, et al. Role of P-glycoprotein in dolastatin 10 resistance. Biochem Pharmacol 1994;48:609-12.